Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00051597 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-30 / ADCETRIS®)

Study Title
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies (NCT00051597)

Trial Description
The purpose of this study is to evaluate a multi-dose regimen of SGN-30, a novel chimeric monoclonal antibody (mAb), in patients with refractory or recurrent CD30+ hematologic malignancies.

This is a single-arm, open-label phase I/II study designed to define the toxicity profile, pharmacokinetic (PK) profile, and anti-tumor activity of a multi-dose regimen of SGN-30 in patients with refractory or recurrent CD30+ hematologic malignancies. The phase I study will be a modified dose escalation of SGN-30. Based on preclinical pharmacology and toxicokinetics (TK) and the first use in human single-dose phase I study, SGN-30 will be administered on a weekly schedule. An initial dose of 2 mg/kg will escalate until the maximum tolerated dose (MTD) has been reached or until a weekly dose of 12 mg/kg is achieved.

This trial is sponsored by Seattle Genetics. [1]

Study Data

  • Conditions:
    • Hodgkin Disease
    • Lymphoma, Large-Cell
    • Sarcoma, Kaposi
    • Lymphoma, T-Cell, Cutaneous
    • Lymphoma, B-Cell
  • Interventions:
    • Drugs used in this trial
      • SGN-30 (Seattle Genetics)
  • Phase: I & II
  • Estimated Enrollment: 70
  • Start:
  • Completion: August 2003
  • Last verified: October 2011

Study Schematic

NCT00051597 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-30 / ADCETRIS®)

Click here to Return to Drug map


Last Editorial review: July 17, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015/ 2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar